The Manufacturers Life Insurance Company Reduces Stake in Becton, Dickinson and Company $BDX

The Manufacturers Life Insurance Company cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 81.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 254,652 shares of the medical instruments supplier’s stock after selling 1,116,528 shares during the quarter. The Manufacturers Life Insurance Company owned 0.09% of Becton, Dickinson and Company worth $38,536,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Tidal Investments LLC raised its stake in shares of Becton, Dickinson and Company by 22.4% during the 2nd quarter. Tidal Investments LLC now owns 146,408 shares of the medical instruments supplier’s stock worth $22,156,000 after buying an additional 26,790 shares during the last quarter. National Pension Service grew its stake in Becton, Dickinson and Company by 7.0% in the 2nd quarter. National Pension Service now owns 596,647 shares of the medical instruments supplier’s stock valued at $90,291,000 after acquiring an additional 38,982 shares during the last quarter. Engineers Gate Manager LP purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $426,000. Cidel Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 9.8% during the 2nd quarter. Cidel Asset Management Inc. now owns 3,124 shares of the medical instruments supplier’s stock valued at $473,000 after acquiring an additional 280 shares in the last quarter. Finally, Capital Analysts LLC raised its position in Becton, Dickinson and Company by 7.5% during the second quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock worth $12,651,000 after acquiring an additional 5,828 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $177.85 on Friday. The company’s 50 day simple moving average is $172.51 and its 200 day simple moving average is $160.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The stock has a market capitalization of $49.00 billion, a PE ratio of 53.57, a P/E/G ratio of 12.53 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 8,005 shares of company stock valued at $1,423,580. Corporate insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

BDX has been the topic of several research reports. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. TD Cowen upped their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Bank of America boosted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $187.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.